RU2017139254A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017139254A3 RU2017139254A3 RU2017139254A RU2017139254A RU2017139254A3 RU 2017139254 A3 RU2017139254 A3 RU 2017139254A3 RU 2017139254 A RU2017139254 A RU 2017139254A RU 2017139254 A RU2017139254 A RU 2017139254A RU 2017139254 A3 RU2017139254 A3 RU 2017139254A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2015/076617 | 2015-04-15 | ||
| CN2015076617 | 2015-04-15 | ||
| PCT/EP2016/057962 WO2016166078A1 (en) | 2015-04-15 | 2016-04-12 | Pyridopyrimidinones and their use as nmda receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017139254A RU2017139254A (ru) | 2019-05-15 |
| RU2017139254A3 true RU2017139254A3 (enExample) | 2019-09-30 |
| RU2717665C2 RU2717665C2 (ru) | 2020-03-24 |
Family
ID=55809078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017139254A RU2717665C2 (ru) | 2015-04-15 | 2016-04-12 | Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10280165B2 (enExample) |
| EP (1) | EP3283487B1 (enExample) |
| JP (2) | JP6847851B2 (enExample) |
| KR (1) | KR20170137137A (enExample) |
| CN (1) | CN107531696B (enExample) |
| AU (1) | AU2016248886B2 (enExample) |
| BR (1) | BR112017021083A2 (enExample) |
| CA (1) | CA2982217A1 (enExample) |
| CL (1) | CL2017002498A1 (enExample) |
| CO (1) | CO2017009989A2 (enExample) |
| CR (1) | CR20170462A (enExample) |
| IL (1) | IL254921B (enExample) |
| MX (1) | MX373162B (enExample) |
| PE (1) | PE20180316A1 (enExample) |
| PH (1) | PH12017501876A1 (enExample) |
| RU (1) | RU2717665C2 (enExample) |
| SG (1) | SG11201708294YA (enExample) |
| UA (1) | UA120647C2 (enExample) |
| WO (1) | WO2016166078A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016007563B1 (pt) | 2013-10-11 | 2022-12-20 | F. Hoffmann-La Roche Ag | Tiazolopirimidinonas, seus usos, e composição farmacêutica |
| SG11201708294YA (en) | 2015-04-15 | 2017-11-29 | Hoffmann La Roche | Pyridopyrimidinones and their use as nmda receptor modulators |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| CA3047403A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Nmda receptor modulators and uses thereof |
| CA3108519A1 (en) | 2018-08-03 | 2020-04-30 | Cadent Therapeutics, Inc. | Heteroaromatic nmda receptor modulators and uses thereof |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| JP7741100B2 (ja) | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| EP1636225B1 (en) * | 2003-06-20 | 2010-02-24 | Novartis Vaccines and Diagnostics, Inc. | Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| JP2010518026A (ja) * | 2007-02-05 | 2010-05-27 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物 |
| WO2014202493A1 (en) * | 2013-06-19 | 2014-12-24 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives |
| BR112016007563B1 (pt) | 2013-10-11 | 2022-12-20 | F. Hoffmann-La Roche Ag | Tiazolopirimidinonas, seus usos, e composição farmacêutica |
| SG11201708294YA (en) | 2015-04-15 | 2017-11-29 | Hoffmann La Roche | Pyridopyrimidinones and their use as nmda receptor modulators |
-
2016
- 2016-04-12 SG SG11201708294YA patent/SG11201708294YA/en unknown
- 2016-04-12 CA CA2982217A patent/CA2982217A1/en not_active Abandoned
- 2016-04-12 RU RU2017139254A patent/RU2717665C2/ru active
- 2016-04-12 CN CN201680021960.3A patent/CN107531696B/zh active Active
- 2016-04-12 EP EP16718618.8A patent/EP3283487B1/en active Active
- 2016-04-12 UA UAA201711077A patent/UA120647C2/uk unknown
- 2016-04-12 CR CR20170462A patent/CR20170462A/es unknown
- 2016-04-12 MX MX2017013101A patent/MX373162B/es active IP Right Grant
- 2016-04-12 PE PE2017002006A patent/PE20180316A1/es unknown
- 2016-04-12 BR BR112017021083-5A patent/BR112017021083A2/pt not_active IP Right Cessation
- 2016-04-12 KR KR1020177032061A patent/KR20170137137A/ko not_active Ceased
- 2016-04-12 JP JP2017553877A patent/JP6847851B2/ja active Active
- 2016-04-12 AU AU2016248886A patent/AU2016248886B2/en not_active Ceased
- 2016-04-12 WO PCT/EP2016/057962 patent/WO2016166078A1/en not_active Ceased
-
2017
- 2017-09-29 CO CONC2017/0009989A patent/CO2017009989A2/es unknown
- 2017-10-03 CL CL2017002498A patent/CL2017002498A1/es unknown
- 2017-10-08 IL IL254921A patent/IL254921B/en active IP Right Grant
- 2017-10-13 PH PH12017501876A patent/PH12017501876A1/en unknown
- 2017-10-13 US US15/783,373 patent/US10280165B2/en active Active
-
2020
- 2020-12-03 JP JP2020200946A patent/JP2021046428A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6847851B2 (ja) | 2021-03-24 |
| US10280165B2 (en) | 2019-05-07 |
| MX373162B (es) | 2020-04-21 |
| PE20180316A1 (es) | 2018-02-09 |
| BR112017021083A2 (pt) | 2018-07-03 |
| EP3283487A1 (en) | 2018-02-21 |
| CA2982217A1 (en) | 2016-10-20 |
| PH12017501876A1 (en) | 2018-02-26 |
| JP2021046428A (ja) | 2021-03-25 |
| US20180127414A1 (en) | 2018-05-10 |
| JP2018511627A (ja) | 2018-04-26 |
| RU2017139254A (ru) | 2019-05-15 |
| AU2016248886B2 (en) | 2020-09-10 |
| CR20170462A (es) | 2018-02-01 |
| EP3283487B1 (en) | 2019-10-16 |
| CO2017009989A2 (es) | 2018-01-05 |
| HK1245259A1 (zh) | 2018-08-24 |
| SG11201708294YA (en) | 2017-11-29 |
| KR20170137137A (ko) | 2017-12-12 |
| RU2717665C2 (ru) | 2020-03-24 |
| CN107531696B (zh) | 2021-03-16 |
| CL2017002498A1 (es) | 2018-04-20 |
| MX2017013101A (es) | 2018-01-30 |
| IL254921B (en) | 2021-02-28 |
| WO2016166078A1 (en) | 2016-10-20 |
| AU2016248886A1 (en) | 2017-10-12 |
| CN107531696A (zh) | 2018-01-02 |
| IL254921A0 (en) | 2017-12-31 |
| UA120647C2 (uk) | 2020-01-10 |